You are here

Category
Technology Name
Briefcase
Scientist
1639
Sphingolipid-peptide conjugates with potent anti-viral activity. According to the WHO, 34 million people around the world are afflicted with HIV, the causative agent of AIDS, with approximately 2.5 million new infections diagnosed each year. The development of new drugs against HIV has been the focus...

Sphingolipid-peptide conjugates with potent anti-viral activity.

According to the WHO, 34 million people around the world are afflicted with HIV, the causative agent of AIDS, with approximately 2.5 million new infections diagnosed each year. The development of new drugs against HIV has been the focus of intense research since its discovery. The market size of HIV-1 treatment is indeed significant with drug sales expected to rise from $13.3 bn in 2011 to $16.7 bn in 2020 in the Western world alone. Nevertheless, there is a highly unmet need for innovative HIV treatment approaches. One such approach is the design of early entry inhibitors that are able to block viral fusion and entry into the host cell. The present technology presents sphingolipid-peptide conjugates (sphingo-peptides) with a potent capacity to interfere with HIV viral fusion.

 

Applications


·         Design of novel HIV therapeutics.

·         Extension of half-life of current HIV fusion inhibitors.

·         Topical blockers of viral transmission.

 


Advantages


  • Blocking viral entry prevents all subsequent intracellular steps, most importantly viral genome integration.
  • Sphingolipid conjugates improve efficacy and half-life of current HIV fusion inhibitors.
  • Sphingopeptides were shown to be effective against certain drug-resistant strains.
  • A unique mode of action that reduces the likelihood of developing resistant strains.

Technology's Essence


The first step in the life cycle of enveloped viruses such as the HIV-1 is entry into their host cells by membrane fusion. Therefore, the dynamic process of HIV fusion and entry represents a valid target for rational drug design. A team of researchers at the Weizmann Institute has developed unique sphingolipid-peptide conjugates that block the fusion of the HIV virus to its host cell membrane. Remarkably, the sphingolipid moiety endowed potent anti-viral activity to otherwise poorly and nonactive peptides. Moreover, the sphingo-peptide inhibitors were shown to be highly effective against both wt as well as drug-resistant HIV strains.

+
  • Prof. Yechiel Shai
1611
Novel HIV-derived peptides for the treatment of T-cell related disorders.Autoimmune diseases affect millions of individuals worldwide and the cost of these diseases, in terms of actual treatment expenditures and lost productivity, is measured in billions of dollars annually. Uncontrolled activation of...

Novel HIV-derived peptides for the treatment of T-cell related disorders.Autoimmune diseases affect millions of individuals worldwide and the cost of these diseases, in terms of actual treatment expenditures and lost productivity, is measured in billions of dollars annually. Uncontrolled activation of T cells is a hallmark of many autoimmune diseases; prominent among these are rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis and Type I diabetes. T cells also play a cardinal role in the rejection for organ transplantation or graft versus host disease. Currently available therapies such as immunosuppressive drugs suppress the patient's entire immune response, thereby increasing the risk of infection, and can cause toxic side effects to non-lymphoid tissues. The development of new immunosuppressive agents capable of selectively inhibiting the activation of T lymphocytes with minimal side effects is therefore desirable. The present invention provides novel peptides endowed with immunosuppressive activity, for the treatment of T-cell related conditions such as autoimmune, inflammatory and graft rejection disorders.

 

Applications


Treatment of various T-cell mediated pathologies including:

  • Autoimmune diseases.
  • Inflammatory disorders.
  • Graft rejection and graft-versus-host disease (GVHD).

 


Advantages


  • The peptides exhibit minimal toxicity.
  • The peptides are about 20 times more potent than the strongest peptide reported from the HIV envelope proteins.
  • The peptides are less hydrophobic than other gp41-derived peptides and as such are more readily soluble in aqueous solution.

Technology's Essence


A team of scientists from the Weizmann Institute has developed peptides, derived from the ectodomain of the HIV gp41 envelope protein, that are able to effectively inhibit T cell activation. These peptides are 20-fold more potent as immunosuppressive peptides compared to other HIV-derived immunosuppressive peptides. The novel gp41-derived peptides robustly attenuated autoimmune disease in vivo, as shown in an experimental autoimmune encephalomyelitis (EAE) animal model, while demonstrating minimal toxic effect in both in vivo and in vitro studies. Furthermore, the novel peptides are remarkably less hydrophobic than other HIV-derived peptides, and therefore can readily dissolve, facilitating their administration as therapeutic agents.

+
  • Prof. Yechiel Shai
1641
A novel RNA-seq method enables unbiased identification and characterization of cell populations from low-quantity samples (~1000 cells). Utilizing tag-free FACS sorting, researchers at the Weizmann Institute are able to create single cell cDNA libraries in under two hours and at a low cost. As...

A novel RNA-seq method enables unbiased identification and characterization of cell populations from low-quantity samples (~1000 cells). Utilizing tag-free FACS sorting, researchers at the Weizmann Institute are able to create single cell cDNA libraries in under two hours and at a low cost.

As personalized medicine requires analysis of minute RNA quantities from patients, there is a great need for unbiased and comprehensive analysis of cells’ transcriptome from low-quantity samples.  Attaining simultaneous observation on millions of cells in their native context is currently a laborious and expensive process. Therefore an unbiased functional characterization of In vivo cell populations is of great demand.

The Researchers have successfully addressed this challenge in a top down fashion by focusing on cell types. Using broad sampling of single cell transcriptional states from multi-cellular tissues they could reconstruct biological functions. They suggest a straightforward path to construct an unbiased map of functional cell states that are sampled directly from their native context. Thus they reveal a new methodology for microscopic analysis of the transcriptome in heterogeneous tissues.

Applications


The innovative technology has potential applications in basic research, personalized medicine and clinical diagnostics -

·         Kits for single cell transcriptome analysis of FACS output.


Advantages


·         Dramatic reduction is costs and labor.

·         High resolution, robust.

·         Top down, unbiased.

·         No need to use markers.


Technology's Essence


This technology combines an automated 384-well cell capture and library preparation assay, two-tier molecular and cellular labeling and efficient poly-A tailed RNA conversion.  Amplification and sequencing of multiplexed libraries is achieved with 1000 cells in a single experiment.  Notably, each read in this method is directly interpretable as representation of a single RNA molecule from a specific single cell. The result is highly practical profiling of large cells samples. This further enables robust characterization of subpopulations’ functional state (at a resolution of 10 cells or 1% of 1000 cells sample).

Moreover the researchers have developed a computational framework that aggressively filters noise and potential biases in the data using randomized molecular labels (RMT) and controls for different sources of amplification and inter-cell contamination errors.
+
  • Prof. Ido Amit
  • Prof. Ido Amit
1618
A novel method is disclosed here for boosting the immune response, useful not only for the treatment of microbial and chronic viral infections, but also for activating the immune system against cancer cells. TLR-4 is a central player in the innate immune system as it specifically recognizes...

A novel method is disclosed here for boosting the immune response, useful not only for the treatment of microbial and chronic viral infections, but also for activating the immune system against cancer cells. TLR-4 is a central player in the innate immune system as it specifically recognizes lipopolysaccharide (LPS), the major cell wall component of Gram-negative bacteria, and activates the immune system. Newly developed peptides derived from the N-terminus of a TLR-4 trans-membrane domain are capable of activating TLR-4 mediated immune response, thus useful both as stand-alone treatments and as vaccine adjuvants, increasing the immunogenicity of an antigen in a vaccine. Taken together, the newly developed peptides are useful for the treatment and prevention of a large variety of infections, such as microbial (e.g. Salmonella, Escherichia, Pseudomonas), viral (including HIV, Hepatitis and Influenza) and fungal infections. Further, they are useful in the treatment and prevention of a wide variety of cancers.

Applications


  • Treatment for a wide variety of infectious diseases and cancers.
  • Prophylaxis for a wide variety of infectious diseases and cancers, as an adjuvant administered together with specific antigen.

Advantages


  • Treats a wide variety of bacterial, viral and fungal infections.
  • Suitable both as a treatment and prophylaxis.
  • Boosts the endogenous immune system
  • Peptides are easy to synthetize and purify
  • Patient-friendly administration, either systemic or local.

Technology's Essence


The technology is based on the discovery that peptides derived from the N-terminus of a TLR-4 TM domain or their analogs are capable of activating TLR-4 mediated immune response. These peptides activate TLR-4 receptor, possibly by dimerizing within the cell membrane and stabilizing the TLR-4 dimer. Through TLR-4 activation, these peptides activate macrophages to secrete TNF-alpha, thereby stimulating the immune system. In addition, the ability of these peptides to modulate the immune system's innate response renders them useful as vaccine adjuvants, increasing the immunogenicity of an antigen in a vaccine.

+
  • Prof. Yechiel Shai
1555
Albumin binding probe for extending the lifetime of drugs. Most polypeptide drugs, in particular non-glycosylated proteins of molecular mass less than 50 kDa, are short-lived species in vivo having circulatory half lives of 5-20 min. Drug association with endogenous albumin may be suitable for...

Albumin binding probe for extending the lifetime of drugs. Most polypeptide drugs, in particular non-glycosylated proteins of molecular mass less than 50 kDa, are short-lived species in vivo having circulatory half lives of 5-20 min. Drug association with endogenous albumin may be suitable for designing an approach to protract the action in vivo of, potentially, any short-lived peptide/protein drug. In doing so two principal obstacles must be overcome: (1) following its conjugation, the probe introduced into a peptide or a protein should have sufficient affinity to albumin to manifest prolonged action in vivo, and (2) in case such covalent introduction results in an inactive product, the latter should be capable to undergo slow reactivation at physiological conditions. The present invention relates to engineering prolonged-acting prodrugs employing an albumin-binding probe that undergoes slow hydrolysis at physiological conditions.

Applications


  • Prolonging half life of short-lined drugs

Advantages


  • Prolonging the action of the drug without effecting its activity 
  • A desirable pharmacokinetic pattern

Technology's Essence


Since albumin is long-lived in vivo, drugs and endogenous substances that tightly associate with it have lower clearance rates than that of the unbound substances, and exhibit prolonged lifetime profiles in vivo. The present invention is based on a concept according to which a long chain fatty acid (LCFA) like albuminbinding compound is covalently linked to a short-lived amino-containing drug to form a non-covalent drug conjugate capable of associating with albumin in vivo, i.e., a long-lived prodrug that gradually releases the pharmacologically active constituent. This approach has been successfully implemented with several drugs (e.g. insulin, exendin and gentamicin).

+
  • Prof. Matityahu Fridkin
  • Prof. Yoram Shechter
1657
Bioengineered formatotrophic E.Coli can be utilized to efficiently generate biomass from electricity. A popular direction for cleantech in recent years is that of biorefineries, that use living organisms to supply the human demand for chemical commodities. Electricity is considered to be a potential...

Bioengineered formatotrophic E.Coli can be utilized to efficiently generate biomass from electricity. A popular direction for cleantech in recent years is that of biorefineries, that use living organisms to supply the human demand for chemical commodities. Electricity is considered to be a potential feedstock for biorefineries, with the end products serving as solid or liquid storage of energy.  Such microbial electrosynthesis is highly dependent on mediators to enable electron transfer from an electrode to a living cell. 
Formic acid (formate) is an electron mediator with a number of desired features for microbial electrosynthesis. However, wild-type organisms that can grow on formate are not suitable for industrial use due to slow growth rates and metabolism. 
Researchers at the Weizmann Institute have successfully engineered a formatotrophic E.coli. By combining systematical analysis with computational tools they screened numerous metabolic pathways and identified the optimized metabolic pathway that supports efficient formate-based growth. This innovative method enables the design of industrial strains of bacteria capable of efficient microbial electrosynthesis.

Applications


  • Biofuel and chemical commodities production.

Advantages


  • Efficient and robust storage of electrical energy.
  • Cost effective conversion of C1 compounds into sugars.

Technology's Essence


By engineering E. coli, the ”workhorse” bacteria used in biotechnology and enabling its growth on formate, researches at Dr. Ron Milo’s lab paved the way for efficient microbial electrosynthesis. The Researches started by investigating many metabolic pathways in order to discover how a model organism such as E.coli can be engineered for formatotrophic growth.  estimate which pathway is most suitable to support growth on formate each pathway was examined based on various criteria such as biomass yield, thermodynamic favorability, chemical motive force, kinetics and additional practical challenges. 
One short favorable pathway was consistently identified, that is the reductive glycine pathway. Furthermore.  Researches generated an isolated organism that is able to convert formate to pyruvate or glycerate.


Licensing Status


Pending

+
  • Prof. Ron Milo
1628
New generation of superior nature-inspired therapeutics for treating inflammation.Inflammation is characterized by elevated levels of TNF-?. Neutralizing TNF-? activity was shown to be beneficial for patients with chronic autoimmune inflammatory diseases such as rheumatoid arthritis (RA) and...

New generation of superior nature-inspired therapeutics for treating inflammation.Inflammation is characterized by elevated levels of TNF-?. Neutralizing TNF-? activity was shown to be beneficial for patients with chronic autoimmune inflammatory diseases such as rheumatoid arthritis (RA) and inflammatory bowel disease (IBD). However, current treatments of such conditions include general anti-inflammatory and immunosuppressive drugs that are of limited effectiveness and may cause serious side effects. Another class of drugs includes targeted therapies directed against TNF-?, that are associated with serious infections including tuberculosis (TB) and sepsis as well as increased risk of cancer in some cases. Thus, there is an urgent need for highly selective, safer and more effective drugs for inflammatory conditions that involve TNF-? as a key mediator. The present technology introduces a novel generation of candidate drugs that selectively inhibit the processing of TNF-?, thereby preventing it from exerting its pro-inflammatory properties. This technology provides a framework for the development of safer and more effective therapeutics for IBD and related autoimmune disorders.

Applications


  • Treatment of autoimmune inflammatory conditions such as IBD and RA.
  • Treatment of neuroinflammatory conditions such as multiple sclerosis (MS).
  • Treatment of other inflammatory mediated diseases such as psoriasis, systemic sclerosis and ankylosing spondylitis.
  • All MMPs and ADAMs proteases possess an autoinhibitory pro-domain and therefore this technology can be broadened to other MMP and ADAM targets.

Advantages


  • TACE pro-domain is highly potent and efficient.
  • TACE pro-domain is metabolically stable, unlike small molecule inhibitors of TACE.
  • Targeting TACE through nature-inspired protein design may constitute a safer approach to combat TNF-? induced inflammation.
  • Unlike non-specific small molecule inhibitors, which target the conserved catalytic zinc site of TACE, TACE pro-domain shares little homology to other MMPs, making it a good candidate for specific inhibitor of TACE.

Technology's Essence


The A disintegrin and metalloproteinase 17 (ADAM17), also known as tumor necrosis factor-? converting enzyme (TACE), has been defined as the major shedding protease for a broad range of substrates predominantly the key immuno-regulatory cytokines TNF-?. Cleavage by TACE renders TNF-? pro-inflammatory, highlighting ADAM17 as a rationale target for treatment of autoimmune diseases such as IBD and arthritis. A team of researchers at the Weizmann institute headed by Prof. Irit Sagi, has employed a sophisticated approach towards TACE targeting by exploiting its autoinhibitory pro-domain as a platform for the ‘smart design’ of TACE selective natural inhibitors. The therapeutic potential of TACE pro-domain was demonstrated in IBD mouse models, where TACE pro-domain administration showed significant improvement in multiple parameters such as reduced mortality and weight lost, in a dose dependent manner. Additional in vivo studies demonstrated that the TACE pro-domain is highly stable in vivo and harbors specificity towards the activated immune cells located in colon lesions. Thus, the novel TACE inhibitor presented in this technology leads to significant therapeutic effects and is beneficial in controlling inflammation in IBD disease manifestations in mice.

+
  • Prof. Irit Sagi
1451
A monoclonal antibody against GluR3B, a peptide found in epilepsy patients, and especially in patients suffering from intractable, resistant forms of the disease, could be used in diagnosis kits as well as in drug development for this form of "autoimmune epilepsy".

A monoclonal antibody against GluR3B, a peptide found in epilepsy patients, and especially in patients suffering from intractable, resistant forms of the disease, could be used in diagnosis kits as well as in drug development for this form of "autoimmune epilepsy".

Applications


1. Producing a new kit for epilepsy patients, able to detect GluR3b Ab's and thus GluR3-mediated neuropathology
The anti GluR3B monoclonal Ab could be used for developing a new diagnostic kit to detect neuropathogenic human anti-GluR3B in serum and CSF of patients with epilepsy. The patient's GluR3B Ab's would compete and displace the GluR3B mAb's of its ligand: the GluR3B peptide. The presence of GluR3B Ab's in a patient, would indicate that autoimmunity against GluR3 may underlie the patient's neuropathology and a) would suggest the initiation of an immune-based therapy b) prevent useless and dangerous brain surgery c) prevent non-effective medication.

2. Drug design for GluR3-mediated neuropathology
The unique GluR3B monoclonal antibody could be used to screen a potential drug for 'Autoimmune Epilepsy'. The GluR3B monoclonal antibody could be used to screen for a molecule (i.e. Anti-idiotypic antibodies) that would block the GluR3 autoantibodies and their detrimental neuropathological effects.

3. Research tool for a kaleidoscope of purposes, including:

  • Detection of the GluR3 glutamate receptor subtype on various target cells.
  • Studies of the properties of the Glutamate/AMPA receptor subtype 3.
  • Studies of the Glutamate-liked agonist activity of the GluR3B monoclonal antibody, and of the GluR3 receptor ion channel gating properties.
  • Production of an animal model of 'Autoimmune Epilepsy'.
  • Studies of neuronal death caused by binding of the GluR3 autoantibody to glutamate/AMPA receptors.
  • Studies of behavioral impairments caused by binding of the GluR3 autoantibody to glutamate/AMPA receptors.

  • Technology's Essence


    Scientists from the Weizmann Institute of Science have discovered a unique anti-GluR3B monoclonal antibody Glu149/29/61.

    +
    • Prof. Vivian I. Teichberg
    • Prof. Vivian I. Teichberg
    1033
    A novel diagnostic test to identify individuals with increased risk of lung cancer. Lung cancer is the number one killer among cancers, with 160,000 deaths/year in the USA and 1.6 million/year worldwide. Early detection of lung cancer increases 5-year survival rate from 4% to 54%. Moreover, the...

    A novel diagnostic test to identify individuals with increased risk of lung cancer.

    Lung cancer is the number one killer among cancers, with 160,000 deaths/year in the USA and 1.6 million/year worldwide. Early detection of lung cancer increases 5-year survival rate from 4% to 54%. Moreover, the National Lung Cancer Trial (NLST) showed that early detection of lung cancer by low-dose CT reduces mortality by at least 20%. Despite recommendations for low-dose CT screening for heavy smokers fulfilling the NLST criteria, compliance is low. In addition, 80 million smokers and ex-smokers in the US who do not fulfil NLST risk criteria have no recommended solution.

    The MyRepair test fulfils this unmet medical need by providing a quantitative prediction of lung cancer risk using a simple blood test. The test is based on a personalized measurement of the patient’s DNA repair capacity, a mechanism which is highly connected to the onset of cancer. Therefore, the MyRepair technology can potentially increase early detection of lung cancer and thus save lives.

     

    Applications


    A novel diagnostic test to identify individuals with increased risk of lung cancer


    Advantages


    ·         Simplicity – MyRepair is based on a simple, cost-effective blood test.

    ·         Accessibility – Compared to low-dose CT which requires specific equipment, the MyRepair test can be easily integrated in general diagnostic labs and therefore may be more accessible to a larger portion of the population.

    ·         Additional applications – Since the test is based on measuring personalized DNA repair mechanism, it can be adopted in the future for the diagnosis of additional cancer types and DNA repair related diseases.


    Technology's Essence


    Based on the strong and well documented connection between impaired capacity for DNA repair and onset of cancer, the Livneh lab invented the MyRepair Test, a method for predicting lung cancer risk, based on measuring activity of 3 DNA repair enzymes.

    Combining enzyme activities with experimental risk estimates generated MyRepair Score, which measures personalized DNA repair capacity of tested subjects.

    An epidemiological/clinical study performed in Israel, further validated in an independent UK study, demonstrated that lung cancer patients have lower MyRepair Score than healthy people. In addition, subjects who test MyRepair-positive have an 85-fold higher risk to develop lung cancer compared to the general population.

    Low MyRepair Score is a risk factor independent of smoking, and of comparable magnitude, indicating that it can be a prognostic tool for smokers, ex-smokers, and non-smokers.

    +
    • Prof. Zvi Livneh
    1518
    Improved immunotherapy for breast cancer. Monoclonal antibodies (mAbs) to ErbB-2/HER2 growth factor receptor, or to its sibling, the epidermal growth factor receptor (EGFR), prolong survival of cancer patients, especially when combined with cytotoxic therapies. However, low effectiveness of...

    Improved immunotherapy for breast cancer.

    Monoclonal antibodies (mAbs) to ErbB-2/HER2 growth factor receptor, or to its sibling, the epidermal growth factor receptor (EGFR), prolong survival of cancer patients, especially when combined with cytotoxic therapies. However, low effectiveness of therapeutic mAbs and the evolution of patient resistance call for improvements. Furthermore, the response to the clinically approved monotherapy of Herceptin (a humanized mAb directed against ErbB-2), is relatively low (~15%) and short lived (median duration, 9 months). Therefore, there is a need to improve the therapeutic treatment against this receptor. The present technology enhances the therapeutic activity of anti-ErB-2 receptor antibodies, by combining two or more epitope-distinct antibodies.

    Applications


    • Improved treatment of ErbB-2-overexpressing tumors (e.g. in breast and ovary cancers).


    Advantages


    • May enhance patient response and delay acquisition of resistance.
    • Enhancement of therapeutic efficacy and synergy with chemotherapy.

    Technology's Essence


    Optimal selection of mAbs for cancer immunotherapy may improve its therapeutic potential. The outlined technology addresses an emerging strategy, which enhances the therapeutic activity of anti-receptor antibodies by combining two mAbs engaging distinct epitopes. It was demonstrated that pairs of anti-ErbB-2 mAbs better inhibit ErbB-2-overexpressing tumors than the respective individual mAbs, both in vitro and in vivo.

    +
    • Prof. Yosef Yarden
    1270
    Monoclonal antibodies to IgE Description: Rat monoclonal anti-IgE antibodies that was generated by fusion of plasmacytoma (84.1C) or myeloma (EM953) cells with splenocytes of rat immunized with purified murine IgE mAb. The antibodies react with various IgE mAb of different specificities and not with...

    Monoclonal antibodies to IgE

    Description: Rat monoclonal anti-IgE antibodies that was generated by fusion of plasmacytoma (84.1C) or myeloma (EM953) cells with splenocytes of rat immunized with purified murine IgE mAb. The antibodies react with various IgE mAb of different specificities and not with immunoglobulins of other classes, and recognize an epitope on the murine Fc epsilon region.

    Were shown to block IgE-Fc?R interactions and inhibit passive cutaneous anaphylaxis. 

    Clone 84.1c recognizes a site on IgE, which is identical or very close to the Fc?R binding site. May be used for detection and manipulation of the IgE response in mice.

    Reference:  Schwarzbaum S, Nissim A, Alkalay I, Ghozi MC, Schindler DG, Bergman Y, Eshhar Z. 1989. Mapping of murine IgE epitopes involved in IgE-Fc epsilon receptor interactions. Eur J Immunol 19(6):1015-23.

     

    M182, M185, M186

    +
    • Prof. Zelig Eshhar
    1397
    A novel antibody which can be used, for the first time, to recognize ubiquitinated histone 2B. This technology is novel in its ability to recognize proteins and their destinations, and may serve in diagnostics and immunoprecipitation processes.

    A novel antibody which can be used, for the first time, to recognize ubiquitinated histone 2B. This technology is novel in its ability to recognize proteins and their destinations, and may serve in diagnostics and immunoprecipitation processes.

    Applications


    Primary applications in research. Use as a detection tool in western blotting, immunoprecipitation and chromatin immunoprecipitation. Might be used for monitoring processes associated with modulations of ubiquitinated-H2B levels.

    Technology's Essence


    The invention involves the generation of antibodies specific to ubiquitinated-H2B which selectively recognize H2B when it is ubiquitinated but not H2B in its unmodified state, or ubiquitin unconjugated to H2B.

    +
    • Prof. Moshe Oren
    1441
    New protein as a target to treat B cell-related cancer.Chronic lymphocytic leukemia (CLL), a malignant disease characterized by the accumulation of B lymphocytes in the blood, lymphoid organs, and bone marrow, is the second most common type of leukemia in adults, accounting for about 7,000 new cases of...

    New protein as a target to treat B cell-related cancer.
    Chronic lymphocytic leukemia (CLL), a malignant disease characterized by the accumulation of B lymphocytes in the blood, lymphoid organs, and bone marrow, is the second most common type of leukemia in adults, accounting for about 7,000 new cases of leukemia each year. Presently, there is no cure for CLL, and the overall goal of leukemia treatment is to bring about a remission. Therefore, identifying new proteins that may serve as a target for inducing cell death in the malignant cells is highly desirable. The present technology identifies a new regulator protein that is essential for the survival of CLL cells.

    Applications


    • Treatment of CLL, as well as other B cell-related cancers (e.g. gastric cancer and renal cell carcinoma), by blocking CD84 activity
    • Diagnosis of CLL

    Advantages


    • Very specific to malignant B cells
    • Diagnosis, and therefore treatment, can be made at early stages of the disease

     


    Technology's Essence


    B cells taken from CLL patients have a high level of the protein CD84. Stimulation of CD84 upregulates the survival of B-CLL. However, inhibition of CD84 activity with a blocking antibody downregulates the expression of another protein which controls B-CLL survival, thus inducing cell death. Therefore, the present invention reveals CD84 as a regulator of B-CLL survival

    +
    • Prof. Idit Shachar
    1499
    Bladder cancer is a common malignancy; it is the 4th most common cancer in males and the 9th in females.  The presenting symptom is usually blood in the urine, and diagnosis is currently based on cystoscopy, which is invasive, costly, painful and time consuming.  To date, no biomarker has been...

    Bladder cancer is a common malignancy; it is the 4th most common cancer in males and the 9th in females.  The presenting symptom is usually blood in the urine, and diagnosis is currently based on cystoscopy, which is invasive, costly, painful and time consuming.  To date, no biomarker has been identified in the urine that might be used for screening, staging, prognosis and monitoring treatment.  We now report that the amount of the 60 kDa heat shock protein (HSP60) in a subject’s urine is a biomarker for muscle invasion in patients with bladder cancer – stage T2 and higher.  Moreover, subjects with stage T1 disease can be stratified by their urine levels of HSP60 into a sub-group likely to progress into stage T2 or into a sub-group more likely to respond to conservative treatment with BCG, which does not require removal of the bladder.  The distinction between these two sub-groups of T1 bladder cancer can identify earlier subjects in need of cystectomy, while sparing others unnecessary major surgery.

    Applications


    • Screening subjects with overt hematuria, or at risk of developing bladder cancer (such as heavy smokers)
    • tratifying bladder cancer subjects
    • Prognosis
    • Determining treatment program
    • Monitoring response to therapy.

    Advantages


    • Non-invasive
    • Easy to apply
    • Relatively inexpensive
    • Prognositic.

    Technology's Essence


    Quantitative measurement of HSP60 levels in a subject’s urine by ELISA, radio-immunoassay or other simple assays.

    +
    • Prof. Irun R. Cohen
    1245

    Applications


    The novel DNA Aptamer is a promising candidate for therapeutic as well as diagnostic uses: Therapeutic: A novel therapy for Influenza Diagnostics: Detection of Influenza infection in vertebrates such as avian, swine and human

    Technology's Essence


    Scientists at the Weizmann Institute of Science describe a novel oligonucleotide, also known as an Aptamer, which has been designed to complement the receptor-binding region of the influenza haemagglutinin molecule. It was constructed by screening a DNA library and processing by the SELEX procedure. This DNA Aptamer comprises of a polynucleotide sequence that can bind to a polypeptide within the binding region of the influenza virus to the host cell. The proposed mode of action of this Aptamer is by blocking the binding of influenza virus to target cell receptors and consequently preventing the virus invasion into the host cells. Aptamer is capable of inhibiting the haemagglutinin capacity of the virus and the viral infectivity in vitro. Furthermore, it was shown in an animal model to inhibit viral infection by different influenza strains, as manifested by up to 99% reduction of virus burden in the lungs of treated mice.

    +
    • Prof. Ruth Arnon

    Pages